The tools to screen for cervical cancer at home now exist. The challenge is getting them used. In a July 2026 article in 360Dx, a GenomeWeb publication, industry stakeholders described a clear pattern: despite multiple FDA approvals for at-home HPV self-collection, uptake of these solutions has lagged. The reporting from GenomeWeb's 360Dx points to a gap that is not about the science of HPV testing, but about the infrastructure around it. That is exactly where health plans come in.
The GenomeWeb 360Dx article, “Despite FDA Approvals, Increased Patient Education, Uptake of Self-Collection for HPV Testing Lags,” gathered perspectives from physicians and researchers across the country. Their consensus: self-collection has strong clinical evidence behind it and clear benefits for patients, yet adoption has been slow. The barriers cited were practical ones, including clinician awareness, clinic workflows built for in-office collection, and the follow-up pathway after a positive result. In other words, an approved test is only the starting point.
SNT Biotech founder and CEO Shital Daftari, quoted in the GenomeWeb 360Dx article, put it directly: “just having an FDA-approved test is not enough.” Health plans, she noted, are beginning to look at how they can engage their populations and encourage screening, and they need to meet members where they are. The point is simple and important. A validated kit sitting on a shelf, or arriving at a home without support around it, does not move a cervical cancer screening rate. What moves the rate is a system that reaches the member, explains the test, and makes completion easy.
According to the reporting in GenomeWeb's 360Dx, one of the biggest hurdles is getting people to return their swabs. This is where a health plan's reach becomes a genuine advantage. Plans already hold the member relationship, the eligibility data, and the outreach channels. Paired with an integrated screening partner, that reach turns an approved test into completed screenings. Multilingual, omni-channel outreach by text, phone, email, and mail, along with prepaid return and active nudges, is what lifts the kit return rate that ultimately decides whether the HEDIS Cervical Cancer Screening (CCS) gap closes.
SNT Biotech works with health plans as a go-to-market partner to deliver the FDA-cleared BD Onclarity HPV Self-Collection Kit directly to members who are overdue for screening. The model runs end to end: member identification, education and outreach, kit fulfillment, processing in our own CLIA-certified and COLA-accredited laboratory, and results delivered to members, primary care physicians, and health plan quality teams through real-time dashboards. That wholly integrated approach, rather than the test alone, is what the voices in GenomeWeb's 360Dx describe as the missing piece.
Timing raises the stakes. Beginning in 2027, federal guidelines will require most private plans to cover self-collected HPV tests with no out-of-pocket cost to members. Plans that build the outreach, return, and follow-up infrastructure now will be ready to reach their under-screened members as coverage expands, rather than starting from zero. The window that GenomeWeb's 360Dx describes, between approval and adoption, is precisely the window health plans can close.
Read the full GenomeWeb 360Dx article, Despite FDA Approvals, Increased Patient Education, Uptake of Self-Collection for HPV Testing Lags, or see our coverage summary and our cervical cancer screening program for health plans.
Quotations are attributed to their source in 360Dx, a GenomeWeb publication (GenomeWeb is a business of Crain Communications), and used for commentary. This article is general information for health plans and is not medical advice. BD Onclarity is a trademark of Becton, Dickinson and Company. HEDIS is a registered trademark of the National Committee for Quality Assurance (NCQA).
See how SNT Biotech helps health plans close the cervical cancer screening gap with at-home HPV self-collection.